C-Terminal Fibronectin Exerts Beneficial Effects in Reducing Tissue Damage and Modulating Macrophage Function in a Murine Septic Model

Background Fibronectin (FN) can improve organ function and slow the progression of sepsis, but full-length FN is hard to be exacted as a therapeutic. Objective This study aimed to investigate the beneficial effects of C-terminal heparin-binding domain polypeptide of FN (rhFNHC-36) in a cecal ligation and puncture (CLP)-mediated murine septic model and explore its regulatory effects on macrophages. Methods Mice were randomly assigned to four groups: unoperated control (Normal), sham operation control (Sham), CLP-operation with intravenous injection of phosphate-buffered saline (CLP+PBS), and CLP-operation with rhFNHC-36 treatment (CLP+rhFNHC-36). Blood and abdominal fluid samples were subjected to bacterial colony formation assays. Organs (liver, spleen, and lung) were undergone histopathological analyses and/or weighed to obtain organ indices. Serum interleukin-6 (IL-6) levels, nitric oxide (NO) release from isolated abdominal macrophages, and chemotactic effect of macrophages were measured with commercial kits. Surface programmed death ligand 1 (PD-L1) expression on macrophages was measured by flow cytometry. Results Mice in the CLP+PBS group showed a lower survival rate than that in the CLP+rhFNHC-36 group. Improved survival was associated with better clearance of bacterial pathogens, as evidenced by colony formation assays. The CLP-induced decrease in thymus and spleen indices was attenuated by rhFNHC-36 treatments. rhFNHC-36 alleviated sepsis-associated tissue damage in liver, spleen, and lung. CLP-mediated increases in plasma IL-6 levels were reversed by rhFNHC-36 treatment. NO levels in peritoneal macrophages after lipopolysaccharides (LPS)-stimulation in the CLP+rhFNHC-36 group were lower than that in the CLP+PBS group. Notably, macrophages from the CLP+rhFNHC-36 group retained better chemotaxis ability. After LPS challenge, these macrophages had a reduced percentage of PD-L1-positive cells compared to those in the CLP+PBS group. Conclusion rhFNHC-36 improved survival of mice with CLP-induced sepsis by reducing tissue damage and modulating macrophage function. Our work provides critical insight for developing FN-based and macrophages-targeted therapeutics for treating sepsis.

[1]  M. I. Sari,et al.  The Expression Levels and Concentrations of PD-1 and PD-L1 Proteins in Septic Patients: A Systematic Review , 2022, Diagnostics.

[2]  Song-Tao Shou,et al.  The roles of macrophage polarization in the host immune response to sepsis. , 2021, International immunopharmacology.

[3]  Lixin Zhou,et al.  PD-1 signaling pathway in sepsis: Does it have a future? , 2021, Clinical immunology.

[4]  M. Shimaoka,et al.  Immune Deregulation in Sepsis and Septic Shock: Reversing Immune Paralysis by Targeting PD-1/PD-L1 Pathway , 2021, Frontiers in Immunology.

[5]  E. Giamarellos‐Bourboulis,et al.  Monitoring immunomodulation in patients with sepsis , 2020, Expert review of molecular diagnostics.

[6]  Peng Ye,et al.  Paeonol promotes the phagocytic ability of macrophages through confining HMGB1 to the nucleus. , 2020, International immunopharmacology.

[7]  A. Mantovani,et al.  Diversity, Mechanisms, and Significance of Macrophage Plasticity. , 2020, Annual review of pathology.

[8]  Niranjan Kissoon,et al.  Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study , 2020, The Lancet.

[9]  S. Lambden.  Bench to bedside review: therapeutic modulation of nitric oxide in sepsis—an update , 2019, Intensive Care Medicine Experimental.

[10]  Jingqian Su,et al.  The Pathogenesis of Sepsis and Potential Therapeutic Targets , 2019, International journal of molecular sciences.

[11]  Anne J. Hunt.  Sepsis: an overview of the signs, symptoms, diagnosis, treatment and pathophysiology. , 2019, Emergency nurse : the journal of the RCN Accident and Emergency Nursing Association.

[12]  M. Borca,et al.  The Role of Interleukin 6 During Viral Infections , 2019, Front. Microbiol..

[13]  Yu Cao,et al.  Park 7: A Novel Therapeutic Target for Macrophages in Sepsis-Induced Immunosuppression , 2018, Front. Immunol..

[14]  Jin Zhang,et al.  Review: the Role and Mechanisms of Macrophage Autophagy in Sepsis , 2018, Inflammation.

[15]  P. Proost,et al.  Chemokine-Induced Macrophage Polarization in Inflammatory Conditions , 2018, Front. Immunol..

[16]  Fang Yang,et al.  Extraction of Cell-Free Whole Blood Plasma Using a Dielectrophoresis-Based Microfluidic Device. , 2018, Biotechnology journal.

[17]  Vijay Kumar,et al.  Targeting macrophage immunometabolism: Dawn in the darkness of sepsis. , 2018, International immunopharmacology.

[18]  A. Goetz,et al.  Markers of nitric oxide are associated with sepsis severity: an observational study , 2017, Critical Care.

[19]  M. Netea,et al.  The immunopathology of sepsis and potential therapeutic targets , 2017, Nature Reviews Immunology.

[20]  D. Angus,et al.  Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations. , 2016, American journal of respiratory and critical care medicine.

[21]  K. Bortoluci,et al.  Revisiting Mouse Peritoneal Macrophages: Heterogeneity, Development, and Function , 2015, Front. Immunol..

[22]  U. Schaible,et al.  Macrophage defense mechanisms against intracellular bacteria , 2015, Immunological reviews.

[23]  Toshio Tanaka,et al.  IL-6 in inflammation, immunity, and disease. , 2014, Cold Spring Harbor perspectives in biology.

[24]  Jia-feng Wang,et al.  PD-L1 Blockade Attenuated Sepsis-Induced Liver Injury in a Mouse Cecal Ligation and Puncture Model , 2013, Mediators of inflammation.

[25]  J. Bernhagen,et al.  Cytokines in Sepsis: Potent Immunoregulators and Potential Therapeutic Targets—An Updated View , 2013, Mediators of inflammation.

[26]  Thomas A. Wynn,et al.  Macrophage biology in development, homeostasis and disease , 2013, Nature.

[27]  C. Sprung,et al.  Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012 , 2013, Intensive Care Medicine.

[28]  M. Mamani,et al.  Evaluation of fibronectin and C-reactive protein levels in patients with sepsis: a case-control study. , 2012, Acta medica Iranica.

[29]  E. Pamer,et al.  Monocyte recruitment during infection and inflammation , 2011, Nature Reviews Immunology.

[30]  C. Libert,et al.  Cecal ligation and puncture: the gold standard model for polymicrobial sepsis? , 2011, Trends in microbiology.

[31]  R. Rodrigo,et al.  Oxidative stress as a novel target in pediatric sepsis management. , 2011, Journal of critical care.

[32]  Hemant Agrawal,et al.  Diversity of Interferon γ and Granulocyte-Macrophage Colony-Stimulating Factor in Restoring Immune Dysfunction of Dendritic Cells and Macrophages During Polymicrobial Sepsis , 2008, Molecular medicine.

[33]  Kazuo Kobayashi,et al.  Macrophages in inflammation. , 2005, Current drug targets. Inflammation and allergy.

[34]  R. Struthers,et al.  A high-throughput chemotaxis assay for pharmacological characterization of chemokine receptors: Utilization of U937 monocytic cells. , 2005, Journal of pharmacological and toxicological methods.

[35]  J. Prieto Prieto,et al.  Plasma fibronectin as a marker of sepsis. , 2004, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[36]  Ping Chen,et al.  Recombinant fibronectin polypeptide antagonizes hepatic failure induced by endotoxin in mice. , 2004, Acta pharmacologica Sinica.

[37]  R. Balk.  Optimum treatment of severe sepsis and septic shock: evidence in support of the recommendations. , 2004, Disease-a-month : DM.

[38]  T. Yoshino,et al.  Differential role of CD80 and CD86 molecules in the induction and the effector phases of allergic rhinitis in mice. , 2001, American journal of respiratory and critical care medicine.

[39]  Christian Bogdan,et al.  Nitric oxide and the immune response , 2001, Nature Immunology.

[40]  J. Cohen,et al.  Evidence of increased nitric oxide production in patients with the sepsis syndrome. , 1993, Circulatory shock.

[41]  T. Clemmer,et al.  Fibronectin in severe sepsis. , 1986, Surgery, gynecology & obstetrics.

[42]  C. Nathan,et al.  Macrophage oxygen-dependent antimicrobial activity. II. The role of oxygen intermediates , 1979, The Journal of experimental medicine.

[43]  Yi Liu,et al.  Interleukin-17D Aggravates Sepsis by Inhibiting Macrophage Phagocytosis. , 2019, Critical care medicine.

[44]  Tao Zhang,et al.  C-terminal heparin-binding domain polypeptide derived from plasma fibronectin , rhFNHC 36 , protects endotoxemia mice by preventing inflammatory responses and increasing the activity of Th lymphocytes , 2017 .

[45]  D. Rittirsch,et al.  Immunodesign of experimental sepsis by cecal ligation and puncture , 2008, Nature Protocols.

[46]  C. Nathan,et al.  Nitric oxide and macrophage function. , 1997, Annual review of immunology.